Skip to main content
SpringerLink
Log in

Infectious Complications in Inflammatory Bowel Disease

  • Chapter
  • First Online:
Inflammatory Bowel Disease

Part of the book series: Clinical Gastroenterology ((CG))

  • 1269 Accesses

Abstract

Therapy for inflammatory bowel disease (IBD) has advanced significantly in recent years, allowing for better control of symptoms and improved quality of life for many patients. With better control, however, comes increased risk, as many newer therapies have profound effects on immune system function and therefore predispose to a wide variety of infectious complications. Herein we describe the newer therapies available for IBD and their mechanisms of action that may lead to increased risk of infection. We also detail potential infectious risks and how to anticipate and prevent them by utilizing historical information, screening mechanisms, and vaccination.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8(6):458–66.

    Article  CAS  PubMed  Google Scholar 

  2. McCurdy JD, Enders FT, Khanna S, Bruining DH, Jones A, Killian JM, et al. Increased rates of Clostridium difficile infection and poor outcomes in patients with IBD with cytomegalovirus. Inflamm Bowel Dis. 2016;22(11):2688–93.

    Article  PubMed  Google Scholar 

  3. Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345–51.

    Article  PubMed  Google Scholar 

  4. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):339–44.

    Article  PubMed  Google Scholar 

  5. Irving PM, Gibson PR. Infections and IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5(1):18–27.

    Article  PubMed  Google Scholar 

  6. Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci. 2018;19(8)

    Google Scholar 

  7. Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn's disease: optimising the old and maximising the new. F1000Res. 2019;8

    Google Scholar 

  9. Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. 2019;68(1):25–39.

    Article  CAS  PubMed  Google Scholar 

  10. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017;66(5):839–51.

    Article  CAS  PubMed  Google Scholar 

  11. Borman ZA, Cote-Daigneault J, Colombel JF. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. Expert Rev Gastroenterol Hepatol. 2018;12(11):1101–8.

    Article  CAS  PubMed  Google Scholar 

  12. FDA Highlights of Prescribing Information: Stelara (ustekinumab). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761044s003lbl.pdf.

  13. Armuzzi A, Ardizzone S, Biancone L, Castiglione F, Danese S, Gionchetti P, et al. Ustekinumab in the management of Crohn's disease: expert opinion. Dig Liver Dis. 2018;50(7):653–60.

    Article  CAS  PubMed  Google Scholar 

  14. Zabotti A, Goletti D, Lubrano E, Cantini F. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opin Drug Saf. 2020;19(1):69–82.

    Article  CAS  PubMed  Google Scholar 

  15. Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1133–8.

    Article  CAS  PubMed  Google Scholar 

  16. De Vries LCS, Wildenberg ME, De Jonge WJ, D'Haens GR. The future of Janus kinase inhibitors in inflammatory bowel disease. J Crohns Colitis. 2017;11(7):885–93.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Global Tuberculosis Report, Executive Summary 2019. Available from: https://www.who.int/tb/data/en/.

  18. Langer AJ, Navin TR, Winston CA, LoBue P. Epidemiology of tuberculosis in the United States. Clin Chest Med. 2019;40(4):693–702.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Muefong CN, Sutherland JS. Neutrophils in tuberculosis-associated inflammation and lung pathology. Front Immunol. 2020;11:962.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chirch LM, Cataline PR, Dieckhaus KD, Grant-Kels JM. Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part I. Risks associated with tumor necrosis factor-alfa antagonists. J Am Acad Dermatol. 2014;71(1):1 e–8; quiz 1 e8–9, 10.

    Article  Google Scholar 

  21. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol. 2013;31:475–527.

    Article  CAS  PubMed  Google Scholar 

  22. Shim HH, Cai SCS, Chan W, Low JGH, Tan HH, Ling KL. Mycobacterium abscessus infection during ustekinumab treatment in Crohn's disease: a case report and review of the literature. J Crohns Colitis. 2018;12(12):1505–7.

    PubMed  Google Scholar 

  23. Ng SC, Hilmi IN, Blake A, Bhayat F, Adsul S, Khan QR, et al. Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting. Inflamm Bowel Dis. 2018;24(11):2431–41.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Desai AA, Marks DJ. Atypical mycobacteria: showerheads, anti-TNF therapy and Crohn's disease. Expert Rev Clin Immunol. 2010;6(5):695–9.

    Article  PubMed  Google Scholar 

  25. Hamilton KA, Ahmed W, Toze S, Haas CN. Human health risks for Legionella and Mycobacterium avium complex (MAC) from potable and non-potable uses of roof-harvested rainwater. Water Res. 2017;119:288–303.

    Article  CAS  PubMed  Google Scholar 

  26. Mohar SM, Saeed S, Ramcharan A, Depaz H. Small bowel obstruction due to mesenteric abscess caused by Mycobacterium avium complex in an HIV patient: a case report and literature review. J Surg Case Rep. 2017;2017(7):rjx129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Griffith DE. Treatment of Mycobacterium avium Complex (MAC). Semin Respir Crit Care Med. 2018;39(3):351–61.

    Article  PubMed  Google Scholar 

  28. CDC Mycobacterium. Available from: https://www.cdc.gov/hai/organisms/mycobacterium.html.

  29. Doudier B, Quiles-Tsimaratos N, Arniaud D. Sporotrichoid non-tuberculous mycobacterial infections following anti-TNF treatment. Med Mal Infect. 2018;48(3):222–5.

    Article  CAS  PubMed  Google Scholar 

  30. Aubry A, Mougari F, Reibel F, Cambau E. Mycobacterium marinum. Microbiol Spectr. 2017;5(2)

    Google Scholar 

  31. Yoo JW, Jo KW, Kang BH, Kim MY, Yoo B, Lee CK, et al. Mycobacterial diseases developed during anti-tumour necrosis factor-alpha therapy. Eur Respir J. 2014;44(5):1289–95.

    Article  CAS  PubMed  Google Scholar 

  32. Fernandez-Ruiz M, Aguado JM. Risk of infection associated with anti-TNF-alpha therapy. Expert Rev Anti-Infect Ther. 2018;16(12):939–56.

    Article  CAS  PubMed  Google Scholar 

  33. Stratton L, Caddy GR. Listeria rhombencephalitis complicating anti-TNF treatment during an acute flare of Crohn's colitis. Case Rep Gastrointest Med. 2016;2016:6216128.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Nugent Z, Singh H, Targownik LE, Bernstein CN. Herpes zoster infection and herpes zoster vaccination in a population-based sample of persons with IBD: is there still an unmet need? Inflamm Bowel Dis. 2019;25(3):532–40.

    Article  PubMed  Google Scholar 

  36. Cote-Daigneault J, Bessissow T, Nicolae MV, Nie R, Bitton A, Lakatos PL, et al. Herpes zoster incidence in inflammatory bowel disease patients: a population-based study. Inflamm Bowel Dis. 2019;25(5):914–8.

    Article  PubMed  Google Scholar 

  37. Click B, Regueiro M. Managing risks with biologics. Curr Gastroenterol Rep. 2019;21(2):1.

    Article  PubMed  Google Scholar 

  38. Bollea-Garlatti ML, Bollea-Garlatti LA, Vacas AS, Torre AC, Kowalczuk AM, Galimberti RL, et al. Clinical characteristics and outcomes in a population with disseminated herpes zoster: a retrospective cohort study. Actas Dermosifiliogr. 2017;108(2):145–52.

    Article  CAS  PubMed  Google Scholar 

  39. Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24(10):2258–65.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6(1)

    Google Scholar 

  41. Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. Psoriasis (Auckl). 2017;7:35–40.

    CAS  Google Scholar 

  42. Degasperi E, Caprioli F, El Sherif O, Back D, Colombo M, Aghemo A. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. Expert Rev Gastroenterol Hepatol. 2016;10(12):1373–83.

    Article  CAS  PubMed  Google Scholar 

  43. Mysore KR, Leung DH. Hepatitis B and C. Clin Liver Dis. 2018;22(4):703–22.

    Article  PubMed  Google Scholar 

  44. Shah R, Ho EY, Kramer JR, Richardson P, Sansgiry S, El-Serag HB, et al. Hepatitis B virus screening and reactivation in a national VA cohort of patients with inflammatory bowel disease treated with tumor necrosis factor antagonists. Dig Dis Sci. 2018;63(6):1551–7.

    Article  PubMed  Google Scholar 

  45. Salvi M, Macaluso L, Luci C, Mattozzi C, Paolino G, Aprea Y, et al. Safety and efficacy of anti-tumor necrosis factors alpha in patients with psoriasis and chronic hepatitis C. World J Clin Cases. 2016;4(2):49–55.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Mushtaq K, Khan Z, Aziz M, Alyousif ZA, Siddiqui N, Khan MA, et al. Trends and outcomes of fungal infections in hospitalized patients of inflammatory bowel disease: a nationwide analysis. Transl Gastroenterol Hepatol. 2020;5:35.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Bourne EL, Dimou J. Invasive central nervous system aspergillosis in a patient with Crohn's disease after treatment with infliximab and corticosteroids. J Clin Neurosci. 2016;30:163–4.

    Article  PubMed  Google Scholar 

  48. Stamatiades GA, Ioannou P, Petrikkos G, Tsioutis C. Fungal infections in patients with inflammatory bowel disease: a systematic review. Mycoses. 2018;61(6):366–76.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Smeekens SP, Ng A, Kumar V, Johnson MD, Plantinga TS, van Diemen C, et al. Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat Commun. 2013;4:1342.

    Article  PubMed  CAS  Google Scholar 

  50. Aikawa NE, Rosa DT, Del Negro GM, Moraes JC, Ribeiro AC, Saad CG, et al. Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy. Rev Bras Reumatol Engl Ed. 2016;56(6):478–82.

    Article  PubMed  Google Scholar 

  51. CDC Fungal Diseases: Histoplasmosis. Available from: https://www.cdc.gov/fungal/diseases/histoplasmosis/.

  52. CDC Fungal Diseases: Histoplasmosis, Symptoms. Available from: https://www.cdc.gov/fungal/diseases/histoplasmosis/symptoms.html.

  53. CDC Fungal Diseases: Coccidioidomycosis. Available from: https://www.cdc.gov/fungal/diseases/coccidioidomycosis/.

  54. CDC: Fungal Diseases, Coccidioidomycosis, Symptoms. Available from: https://www.cdc.gov/fungal/diseases/coccidioidomycosis/symptoms.html.

  55. CDC Fungal Diseases: Blastomycosis. Available from: https://www.cdc.gov/fungal/diseases/blastomycosis/definition.html.

  56. CDC Fungal Diseases: Blastomycosis, Symptoms. Available from: https://www.cdc.gov/fungal/diseases/blastomycosis/symptoms.html.

  57. Aspergillosis. Available from: https://www.cdc.gov/fungal/diseases/aspergillosis/health-professionals.html.

  58. Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin N Am. 2016;30(1):179–206.

    Article  Google Scholar 

  59. Guillen MC, Alcover MM, Borruel N, Sulleiro E, Salvador F, Berenguer D, et al. Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF therapy. Heliyon. 2020;6(5):e03940.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev. 2004;17(1):208–17.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Baez-Vallecillo L, Stewart BD, Kott MM, Bhattacharjee M. Strongyloides hyperinfection as a mimic of inflammatory bowel disease. Am J Gastroenterol. 2013;108(4):622–3.

    Article  PubMed  Google Scholar 

  62. Khaliq MF, Ihle RE, Perry J. Immunosuppression with antitumour necrosis factor therapy leading to strongyloides hyperinfection syndrome. Case Rep Infect Dis. 2018;2018:6341680.

    PubMed  PubMed Central  Google Scholar 

  63. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443–68.

    Article  CAS  PubMed  Google Scholar 

  64. Wheat LJ, Kauffman CA. Histoplasmosis. Infect Dis Clin N Am. 2003;17(1):1–19, vii.

    Article  Google Scholar 

  65. Sipsas NV, Kontoyiannis DP. Occupation, lifestyle, diet, and invasive fungal infections. Infection. 2008;36(6):515–25.

    Article  CAS  PubMed  Google Scholar 

  66. Gagniere C, Bourrier A, Seksik P, Gornet JM, DeWit O, Nancey S, et al. Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif (GETAID). Aliment Pharmacol Ther. 2018;48(7):713–22.

    Article  CAS  PubMed  Google Scholar 

  67. Martinez FJ, Leffler DA, Kelly CP. Clostridium difficile outbreaks: prevention and treatment strategies. Risk Manag Healthc Policy. 2012;5:55–64.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Tubach F, Ravaud P, Salmon-Ceron D, Petitpain N, Brocq O, Grados F, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis. 2006;43(10):e95–100.

    Article  CAS  PubMed  Google Scholar 

  69. Barros MB, de Almeida PR, Schubach AO. Sporothrix schenckii and Sporotrichosis. Clin Microbiol Rev. 2011;24(4):633–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Cartwright EJ, Jackson KA, Johnson SD, Graves LM, Silk BJ, Mahon BE. Listeriosis outbreaks and associated food vehicles, United States, 1998–2008. Emerg Infect Dis. 2013;19(1):1–9; quiz 184.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Centers for Disease Control and Prevention. Multistate outbreak of listeriosis associated with Jensen Farms cantaloupe–United States, August–September 2011. MMWR Morb Mortal Wkly Rep. 2011;60(39):1357–8.

    Google Scholar 

  72. Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis. 2001;32(2):263–9.

    Article  CAS  PubMed  Google Scholar 

  73. Pappas PG. Cryptococcal infections in non-HIV-infected patients. Trans Am Clin Climatol Assoc. 2013;124:61–79.

    PubMed  PubMed Central  Google Scholar 

  74. Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med. 2015;36(1):91–9.

    Article  PubMed  Google Scholar 

  75. Ferreira J, Grochowsky J, Krakower D, Zuromskis P, Baden R, Cheifetz AS. Mycobacterium marinum: an increasingly common opportunistic infection in patients on infliximab. Am J Gastroenterol. 2012;107(8):1268–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Kump PK, Hogenauer C, Wenzl HH, Petritsch W. A case of opportunistic skin infection with Mycobacterium marinum during adalimumab treatment in a patient with Crohn's disease. J Crohns Colitis. 2013;7(1):e15–8.

    Article  PubMed  Google Scholar 

  77. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965–76.

    Article  CAS  PubMed  Google Scholar 

  78. Mermin J, Hutwagner L, Vugia D, Shallow S, Daily P, Bender J, et al. Reptiles, amphibians, and human Salmonella infection: a population-based, case-control study. Clin Infect Dis. 2004;38 Suppl 3:S253–61.

    Article  PubMed  Google Scholar 

  79. Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012;59(7):C4480.

    PubMed  Google Scholar 

  80. Bradford RD, Pettit AC, Wright PW, Mulligan MJ, Moreland LW, McLain DA, et al. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis. 2009;49(6):924–7.

    Article  PubMed  Google Scholar 

  81. Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin Infect Dis. 2012;54(8):1167–78.

    Article  PubMed  Google Scholar 

  82. Jafari S, Buxton JA, Afshar K, Copes R, Baharlou S. Tattooing and risk of hepatitis B: a systematic review and meta-analysis. Can J Public Health. 2012;103(3):207–12.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Dieckmann R, Boone I, Brockmann SO, Hammerl JA, Kolb-Maurer A, Goebeler M, et al. The risk of bacterial infection after tattooing. Dtsch Arztebl Int. 2016;113(40):665–71.

    PubMed  PubMed Central  Google Scholar 

  84. Bagaitkar J, Demuth DR, Scott DA. Tobacco use increases susceptibility to bacterial infection. Tob Induc Dis. 2008;4:12.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Glickman MS, Schluger N. Adding insult to injury: exacerbating TB risk with smoking. Cell Host Microbe. 2016;19(4):432–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(6):925–32.

    Article  PubMed  Google Scholar 

  87. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53(9):1363–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Belle A, Baumann C, Bigard MA, Zallot C, Gizard E, Gueant JL, et al. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2015;27(8):877–81.

    Article  CAS  PubMed  Google Scholar 

  89. Jansson-Knodell CL, Harris CE, Loftus EV Jr, Walker RC, Enzler MJ, Virk A. Histoplasmosis in inflammatory bowel disease with tumor necrosis factor-alpha inhibitors: safe to continue biologics? Dig Dis Sci. 2021;66(1):190–8.

    Article  CAS  PubMed  Google Scholar 

  90. Chirch LM, Cataline PR, Dieckhaus KD, Grant-Kels JM. Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part II. Screening for patients on tumor necrosis factor-alfa antagonists. J Am Acad Dermatol. 2014;71(1):11 e1–7; quiz 8–20.

    Article  Google Scholar 

  91. Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol. 1990;12(5):562–8.

    Article  CAS  PubMed  Google Scholar 

  92. Koffas A, Dolman GE, Kennedy PT. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clin Med (Lond). 2018;18(3):212–8.

    Article  Google Scholar 

  93. Available from: https://www.cdc.gov/parasites/strongyloides/health_professionals/index.html. 21 Sept 2020.

  94. Farraye FA. Vaccination of patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2017;13(7):431–4.

    Google Scholar 

  95. deBruyn J, Fonseca K, Ghosh S, Panaccione R, Gasia MF, Ueno A, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2016;22(3):638–47.

    Article  PubMed  Google Scholar 

  96. Brogan MD, Shanahan F, Oliver M, Stevens RH, Targan SR. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol. 1987;24(2):69–74.

    CAS  PubMed  Google Scholar 

  97. Nielsen HJ, Mortensen T, Holten-Andersen M, Brunner N, Sorensen S, Rask-Madsen J. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001;36(3):265–9.

    Article  CAS  PubMed  Google Scholar 

  98. Zullow S, Farraye FA. Updates on vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol. 2019;13(3):229–39.

    Article  CAS  PubMed  Google Scholar 

  99. Boltin D, Gingold-Belfer R, Kimchi NA, Ben-Bassat O, Niv Y, Birkenfeld S. Utilization of influenza immunization in adults with Crohn's disease-a longitudinal, population-based study. Inflamm Bowel Dis. 2014;20(2):240–5.

    Article  PubMed  Google Scholar 

  100. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis. 2019;68(6):895–902.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(2):240–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(1):148–54.

    Article  PubMed  Google Scholar 

  103. Reich J, Wasan S, Farraye FA. Vaccinating patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12(9):540–6.

    Google Scholar 

  104. Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabo H, Sociale OR, Vetrano S, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18(6):1042–7.

    Article  PubMed  Google Scholar 

  105. Park SH, Yang SK, Park SK, Kim JW, Yang DH, Jung KW, et al. Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(1):69–74.

    Article  PubMed  Google Scholar 

  106. Montiel PM, Solis JA, Chirinos JA, a Casis B, Sanchez F, Rodriguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int. 2008;28(5):718–20.

    Article  PubMed  Google Scholar 

  107. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(12):1483–90.

    Article  PubMed  Google Scholar 

  108. Moutsopoulos HM, Gallagher JD, Decker JL, Steinberg AD. Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum. 1978;21(7):798–802.

    Article  CAS  PubMed  Google Scholar 

  109. Allegretti JR, Barnes EL, Cameron A. Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis. 2015;21(5):1089–97.

    Article  PubMed  Google Scholar 

  110. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241–58.

    Article  PubMed  Google Scholar 

  111. Devon KM, Brown CJ, Burnstein M, McLeod RS. Cancer of the anus complicating perianal Crohn's disease. Dis Colon Rectum. 2009;52(2):211–6.

    Article  CAS  PubMed  Google Scholar 

  112. Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(7):1441–9.

    Article  PubMed  Google Scholar 

  113. Available from: https://www.cdc.gov/vaccines/vpd/mening/hcp/recommendations.html.

  114. Marin M, Guris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices CfDC, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007;56(RR-4):1–40.

    Google Scholar 

  115. Kim DK, Riley LE, Hunter P. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older – United States, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(5):158–60.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3(2):47–91.

    Article  CAS  PubMed  Google Scholar 

  117. Tsai SY, Yang TY, Lin CL, Tsai YH, Kuo CF, Kao CH. Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study. Int J Clin Pract. 2015;69(2):228–34.

    Article  PubMed  Google Scholar 

  118. Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2392–403.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA

    Alexandra Garten Schmitt, Thomas Erwes & Lisa M. Chirch

Authors
  1. Alexandra Garten Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Erwes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lisa M. Chirch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa M. Chirch .

Editor information

Editors and Affiliations

  1. Zucker School of Medicine at Hofstra/Northwell, Mather Gastroenterology, Port Jefferson, NY, USA

    Ramona Rajapakse

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Garten Schmitt, A., Erwes, T., Chirch, L.M. (2021). Infectious Complications in Inflammatory Bowel Disease. In: Rajapakse, R. (eds) Inflammatory Bowel Disease. Clinical Gastroenterology. Humana, Cham. https://doi.org/10.1007/978-3-030-81780-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-81780-0_6

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-81779-4

  • Online ISBN: 978-3-030-81780-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation